Skip to content
TrialScanner

NCT05226780

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Phase 2TerminatedNBIXLead

Registry record

Lead sponsor
Neurocrine Biosciences
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Primary completion
Nov 12, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05226780 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05226780: Extension Study to Evaluate... | TrialScanner